Details of Disease

General Information of Disease (ID: DIS50C5O)

• Disease Name: Dermatomyositis
• Synonyms: Amyopathic dermatomyositis; adult dermatomyositis; dermatopolymyositis; DM; polymyositis with skin involvement; dermatomyositis
• Disease Class: 4A41: Idiopathic inflammatory myopathy
• Definition: Dermatomyositis (DM) is a type of idiopathic inflammatory myopathy characterized by evocative skin lesions and symmetrical proximal muscle weakness.
• Disease Hierarchy:
  DIS5DHFP: Polymyositis
  DISWD40R: Disease
  DIS77ACK: Rheumatic disorder
  DISY5SZC: Dermatitis
  DIS50C5O: Dermatomyositis
• ICD Code: ICD-11: ICD-11: 4A41.0
• Disease Identifiers:
  MONDO ID: MONDO_0016367
  MESH ID: D003882
  UMLS CUI: C0011633
  MedGen ID: 8331
  Orphanet ID: 221
  SNOMED CT ID: 396230008

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Benzoic Acid	DMKB9FI	Approved	Small molecular drug	[1]

This Disease is Treated as An Indication in 2 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Daxdilimab	DM5BV5H	Phase 2	Monoclonal antibody	[2]
KZR-616	DM6VD4L	Phase 2	Small molecule	[3]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 20 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
BLK	TTNDSC3	Limited	Genetic Variation	[4]
CCL21	TTLZK1U	Limited	Genetic Variation	[5]
CLEC4C	TT7YT06	Limited	Biomarker	[6]
DCPS	TTLSW9V	Limited	Biomarker	[7]
DYSF	TTA7MXQ	Limited	Altered Expression	[8]
IL31	TT1RJXK	Limited	Biomarker	[9]
TRIM24	TT9Q7AE	Limited	Altered Expression	[10]
CASP6	TTKW4ML	Strong	Altered Expression	[11]
CD83	TTT9MRQ	Strong	Altered Expression	[12]
CPN1	TT8V2KD	Strong	Genetic Variation	[13]
DDX58	TTVB0O3	Strong	Biomarker	[14]
HLA-B	TTGS10J	Strong	Genetic Variation	[15]
IFNB1	TT4TZ8J	Strong	Biomarker	[16]
IL1A	TTPM6HI	Strong	Genetic Variation	[17]
IL31RA	TT9HPX0	Strong	Biomarker	[18]
MCHR2	TTS17MG	Strong	Altered Expression	[11]
MYH2	TTBIL13	Strong	Biomarker	[19]
PMS1	TTX1ISF	Strong	Biomarker	[20]
SRGN	TTCHB06	Strong	Biomarker	[21]
TRIM28	TTQ2BKV	Strong	Biomarker	[22]

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC2A10	DT3BI6S	Strong	Altered Expression	[23]

This Disease Is Related to 1 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
AOC2	DE8DP90	Strong	Biomarker	[24]

This Disease Is Related to 51 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CABIN1	OT4G5CIK	Limited	Biomarker	[25]
CACYBP	OTJMZD2T	Limited	Biomarker	[26]
FAM167A	OT9JF3JQ	Limited	Genetic Variation	[4]
KANK2	OT3SZIWM	Limited	Biomarker	[26]
NT5C1A	OTS7UF36	Limited	Biomarker	[27]
PUF60	OTG90DYF	Limited	Biomarker	[28]
RBM14	OTO9GMBD	Limited	Biomarker	[26]
SLURP1	OT89YD2E	Limited	Biomarker	[7]
TP53INP1	OT2363Z9	Limited	Biomarker	[26]
TSACC	OT3QW6PH	Limited	Biomarker	[26]
MPC1	OT6DYFUO	moderate	Altered Expression	[29]
ACTN3	OT9DZ7JQ	Strong	Biomarker	[30]
ANGPTL2	OTB6JG41	Strong	Biomarker	[31]
ANKRD55	OT62KZII	Strong	Altered Expression	[32]
ATP5F1E	OTMPLAIS	Strong	Biomarker	[33]
ATP5IF1	OTQFD73H	Strong	Biomarker	[33]
BANK1	OTXAAA11	Strong	Genetic Variation	[34]
C2	OTHMF4YM	Strong	Biomarker	[35]
C9	OT7I5FDX	Strong	Biomarker	[36]
CD207	OTI9RUDN	Strong	Altered Expression	[37]
CKLF	OTHLPHA0	Strong	Altered Expression	[38]
COL4A5	OTHG60RE	Strong	Altered Expression	[23]
DHX9	OT5AAOQI	Strong	Biomarker	[39]
DNASE1L3	OTEUIMC2	Strong	Altered Expression	[40]
EIF2B5	OTV3R4RB	Strong	Genetic Variation	[41]
GARS1	OT5B6R9Y	Strong	Biomarker	[42]
HERC5	OTZ5PR39	Strong	Altered Expression	[43]
HLA-DPA1	OT7OG7Y2	Strong	Genetic Variation	[13]
HLA-DPB1	OTW8JHU2	Strong	Genetic Variation	[44]
IFI6	OTWOOAM4	Strong	Altered Expression	[45]
IFIH1	OTZA2AHA	Strong	Biomarker	[46]
IFNA1	OTPMKY0L	Strong	Altered Expression	[47]
IL1RAPL2	OTP7IOJO	Strong	Altered Expression	[48]
KARS1	OT0EU4SV	Strong	Biomarker	[49]
KDELR1	OT8YBS5G	Strong	Biomarker	[19]
MB	OTYWYL2D	Strong	Altered Expression	[50]
MORC3	OT81NKVT	Strong	Biomarker	[51]
MX1	OT6X8G5T	Strong	Altered Expression	[52]
NECAP2	OTLH23GP	Strong	Biomarker	[53]
NFAT5	OTKIE59S	Strong	Altered Expression	[54]
PIP	OTH719AH	Strong	Genetic Variation	[13]
PLAAT4	OTI66SAJ	Strong	Altered Expression	[55]
PLCL1	OTJL2C79	Strong	Genetic Variation	[56]
RIT2	OTSNYG0D	Strong	Biomarker	[32]
RMI2	OTA0HP4S	Strong	Biomarker	[57]
RNPC3	OTW5MKC1	Strong	Biomarker	[58]
ROBO3	OTPVG40S	Strong	Biomarker	[14]
RTRAF	OTJ6NVMW	Strong	Genetic Variation	[41]
SFPQ	OTLCIAPJ	Strong	Biomarker	[59]
SYNM	OTOI8TRJ	Strong	Biomarker	[60]
TRIM21	OTA4UJCF	Strong	Biomarker	[61]

References

• [1] Benzoic acid production via cascade biotransformation and coupled fermentation-biotransformation. Biotechnol Bioeng. 2020 Aug;117(8):2340-2350.
• [2] ClinicalTrials.gov (NCT05669014) A Phase 2, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of Daxdilimab Subcutaneous Injection in Adult Participants With Inadequately Controlled Dermatomyositis or Anti-synthetase Inflammatory Myositis. U.S.National Institutes of Health.
• [3] ClinicalTrials.gov (NCT04628936) An Open-label Extension to the Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients With Active Polymyositis or Dermatomyositis. U.S.National Institutes of Health.
• [4] Single nucleotide polymorphisms in the FAM167A-BLK gene are associated with polymyositis/dermatomyositis in the Han Chinese population.Immunol Res. 2015 Jun;62(2):153-62. doi: 10.1007/s12026-015-8646-0.
• [5] A single-nucleotide polymorphism of CCL21 rs951005 T>C is associated with susceptibility of polymyositis and such patients with interstitial lung disease in a Chinese Han population.Clin Exp Rheumatol. 2015 Sep-Oct;33(5):639-46. Epub 2015 Aug 31.
• [6] Role of the chemokine receptors CXCR3, CXCR4 and CCR7 in the intramuscular recruitment of plasmacytoid dendritic cells in dermatomyositis.J Neuroimmunol. 2018 Jun 15;319:142-148. doi: 10.1016/j.jneuroim.2018.01.008. Epub 2018 Jan 9.
• [7] Current understanding and recent advances in myositis-specific and -associated autoantibodies detected in patients with dermatomyositis.Expert Rev Clin Immunol. 2020 Jan;16(1):79-89. doi: 10.1080/1744666X.2019.1699059. Epub 2019 Dec 8.
• [8] Global analysis of protein expression in muscle tissues of dermatomyositis/polymyosisits patients demonstrated an association between dysferlin and human leucocyte antigen A.Rheumatology (Oxford). 2019 Mar 25:kez085. doi: 10.1093/rheumatology/kez085. Online ahead of print.
• [9] Role of the Pruritic Cytokine IL-31 in Autoimmune Skin Diseases.Front Immunol. 2019 Jun 21;10:1383. doi: 10.3389/fimmu.2019.01383. eCollection 2019.
• [10] Anti-TIF1 antibody and the expression of TIF1 in idiopathic inflammatory myopathies.Int J Rheum Dis. 2019 Feb;22(2):314-320. doi: 10.1111/1756-185X.13424. Epub 2018 Nov 5.
• [11] MHC class I and II expression in juvenile dermatomyositis skeletal muscle.Clin Exp Rheumatol. 2009 May-Jun;27(3):519-26.
• [12] Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis.Arthritis Rheum. 2007 May;56(5):1658-68. doi: 10.1002/art.22558.
• [13] Variation at HLA-DPB1 is associated with dermatomyositis in Chinese population.J Dermatol. 2016 Nov;43(11):1307-1313. doi: 10.1111/1346-8138.13397. Epub 2016 May 6.
• [14] The RIG-I pathway is involved in peripheral T cell lymphopenia in patients with dermatomyositis.Arthritis Res Ther. 2019 May 29;21(1):131. doi: 10.1186/s13075-019-1905-z.
• [15] Malignancy as a comorbidity in rheumatic diseases: a retrospective hospital-based study.Clin Rheumatol. 2018 Jan;37(1):81-85. doi: 10.1007/s10067-017-3676-8. Epub 2017 May 16.
• [16] Measurement of cytokines and chemokines and association with clinical severity of dermatomyositis and clinically amyopathic dermatomyositis.Br J Dermatol. 2018 Dec;179(6):1334-1341. doi: 10.1111/bjd.17079. Epub 2018 Oct 7.
• [17] Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis.Arthritis Rheum. 2008 Dec;58(12):3941-50. doi: 10.1002/art.24039.
• [18] Itch in dermatomyositis: the role of increased skin interleukin-31.Br J Dermatol. 2018 Sep;179(3):669-678. doi: 10.1111/bjd.16498. Epub 2018 Jun 21.
• [19] A three-way interplay of DR4, autoantibodies and synovitis in biopsy-proven idiopathic inflammatory myositis.Rheumatol Int. 2012 Mar;32(3):611-9. doi: 10.1007/s00296-010-1637-5. Epub 2010 Dec 2.
• [20] Immune responses to DNA mismatch repair enzymes hMSH2 and hPMS1 in patients with pancreatic cancer, dermatomyositis and polymyositis.Int J Cancer. 2005 Oct 10;116(6):925-33. doi: 10.1002/ijc.21118.
• [21] Identification of specific chondroitin sulfate species in cutaneous autoimmune disease.J Histochem Cytochem. 2011 Aug;59(8):780-90. doi: 10.1369/0022155411411304.
• [22] Autoantibody to transcriptional intermediary factor-1 as a myositis-specific antibody: clinical correlation with clinically amyopathic dermatomyositis or dermatomyositis with mild myopathy.Br J Dermatol. 2019 Apr;180(4):881-887. doi: 10.1111/bjd.17098. Epub 2018 Oct 10.
• [23] Private specificities can dominate the humoral response to self-antigens in patients with cryptogenic fibrosing alveolitis.Respir Res. 2001;2(2):119-24. doi: 10.1186/rr46. Epub 2001 Feb 20.
• [24] Overexpression of semicarbazide-sensitive amine oxidase in human myopathies.Muscle Nerve. 2004 Feb;29(2):261-6. doi: 10.1002/mus.10550.
• [25] Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: A case report.Medicine (Baltimore). 2018 Apr;97(15):e0436. doi: 10.1097/MD.0000000000010436.
• [26] Efficacy and safety of oral high-trough level tacrolimus in acute/subacute interstitial pneumonia with dermatomyositis.Int J Rheum Dis. 2019 Feb;22(2):303-313. doi: 10.1111/1756-185X.13414. Epub 2018 Nov 5.
• [27] Autoantibodies to Cytosolic 5'-Nucleotidase 1A in Primary Sjgren's Syndrome and Systemic Lupus Erythematosus.Front Immunol. 2018 Jun 5;9:1200. doi: 10.3389/fimmu.2018.01200. eCollection 2018.
• [28] Anti-FIRexon2, a splicing variant form of PUF60, autoantibody is detected in the sera of esophageal squamous cell carcinoma.Cancer Sci. 2019 Jun;110(6):2004-2013. doi: 10.1111/cas.14024. Epub 2019 May 20.
• [29] Detection of serum MCP-1 and TGF-1 in polymyositis/dermatomyositis patients and its significance.Eur J Med Res. 2019 Feb 14;24(1):12. doi: 10.1186/s40001-019-0368-7.
• [30] The ACTN3 R577X polymorphism is associated with inflammatory myopathies in a Mexican population.Scand J Rheumatol. 2012 Oct;41(5):396-400. doi: 10.3109/03009742.2012.669495. Epub 2012 May 29.
• [31] The role of angiopoietin-like protein 2 in pathogenesis of dermatomyositis.Biochem Biophys Res Commun. 2012 Feb 17;418(3):494-9. doi: 10.1016/j.bbrc.2012.01.052. Epub 2012 Jan 18.
• [32] T-cell transcriptomics from peripheral blood highlights differences between polymyositis and dermatomyositis patients.Arthritis Res Ther. 2018 Aug 29;20(1):188. doi: 10.1186/s13075-018-1688-7.
• [33] Pyruvate kinase M2 and the mitochondrial ATPase Inhibitory Factor 1 provide novel biomarkers of dermatomyositis: a metabolic link to oncogenesis.J Transl Med. 2017 Feb 10;15(1):29. doi: 10.1186/s12967-017-1136-5.
• [34] Association between the BANK1 rs3733197 polymorphism and polymyositis/dermatomyositis in a Chinese Han population.Clin Rheumatol. 2019 Feb;38(2):431-436. doi: 10.1007/s10067-018-4257-1. Epub 2018 Aug 25.
• [35] Penicillamine induced polymyositis and dermatomyositis.J Rheumatol. 1987 Oct;14(5):995-1001.
• [36] Hereditary complement (C9) deficiency associated with dermatomyositis.Br J Dermatol. 2001 May;144(5):1080-3. doi: 10.1046/j.1365-2133.2001.04204.x.
• [37] Fascin-expressing dendritic cells dominate in polymyositis and dermatomyositis.J Rheumatol. 2013 Feb;40(2):186-91. doi: 10.3899/jrheum.120590. Epub 2012 Nov 1.
• [38] Chemokine-like factor expression in the idiopathic inflammatory myopathies.Acta Neurol Scand. 2008 Aug;118(2):106-14. doi: 10.1111/j.1600-0404.2007.00990.x. Epub 2008 Feb 19.
• [39] Autoantibodies to RNA helicase A: a new serologic marker of early lupus.Arthritis Rheum. 2007 Feb;56(2):596-604. doi: 10.1002/art.22329.
• [40] Serum level of DNase1l3 in patients with dermatomyositis/polymyositis, systemic lupus erythematosus and rheumatoid arthritis, and its association with disease activity.Clin Exp Med. 2017 Nov;17(4):459-465. doi: 10.1007/s10238-016-0448-8. Epub 2016 Dec 30.
• [41] Prevalence of Pruritus in Cutaneous Lupus Erythematosus: Brief Report of a Multicenter, Multinational Cross-Sectional Study.Biomed Res Int. 2018 Jul 25;2018:3491798. doi: 10.1155/2018/3491798. eCollection 2018.
• [42] Primary structure and functional expression of human Glycyl-tRNA synthetase, an autoantigen in myositis.J Biol Chem. 1994 Nov 18;269(46):28790-7.
• [43] Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy.Ann Neurol. 2010 Jan;67(1):53-63. doi: 10.1002/ana.21805.
• [44] Novel susceptibility alleles in HLA region for myositis and myositis specific autoantibodies in Korean patients.Semin Arthritis Rheum. 2019 Oct;49(2):283-287. doi: 10.1016/j.semarthrit.2019.03.005. Epub 2019 Mar 9.
• [45] Discovery of Key Genes in Dermatomyositis Based on the Gene Expression Omnibus Database.DNA Cell Biol. 2018 Oct 31. doi: 10.1089/dna.2018.4256. Online ahead of print.
• [46] Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis.Arthritis Rheumatol. 2020 Mar;72(3):488-498. doi: 10.1002/art.41105. Epub 2020 Jan 27.
• [47] Aberrant activation of the type I interferon system may contribute to the pathogenesis of anti-melanoma differentiation-associated gene 5 dermatomyositis.Br J Dermatol. 2019 May;180(5):1090-1098. doi: 10.1111/bjd.16917. Epub 2018 Sep 26.
• [48] Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies.Arthritis Rheum. 2007 Feb;56(2):674-87. doi: 10.1002/art.22388.
• [49] Lysyl-Transfer RNA Synthetase Induces the Maturation of Dendritic Cells through MAPK and NF-B Pathways, Strongly Contributing to Enhanced Th1 Cell Responses.J Immunol. 2018 Nov 1;201(9):2832-2841. doi: 10.4049/jimmunol.1800386. Epub 2018 Oct 1.
• [50] Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1positive polymyositis and dermatomyositis.Arthritis Res Ther. 2018 Jul 27;20(1):158. doi: 10.1186/s13075-018-1650-8.
• [51] Perimysial microarteriopathy in dermatomyositis with anti-nuclear matrix protein-2 antibodies.Eur J Neurol. 2020 Mar;27(3):514-521. doi: 10.1111/ene.14097. Epub 2019 Oct 25.
• [52] Glomerular expression of myxovirus resistance protein 1 in human mesangial cells: possible activation of innate immunity in the pathogenesis of lupus nephritis.Nephrology (Carlton). 2013 Dec;18(12):833-7. doi: 10.1111/nep.12155.
• [53] Integrated comparison of the miRNAome and mRNAome in muscles of dermatomyositis and polymyositis reveals common and specific miRNA-mRNAs.Epigenomics. 2019 Jan;11(1):23-33. doi: 10.2217/epi-2018-0064. Epub 2018 Dec 7.
• [54] Localization and Expression of Nuclear Factor of Activated T-Cells 5 in Myoblasts Exposed to Pro-inflammatory Cytokines or Hyperosmolar Stress and in Biopsies from Myositis Patients.Front Physiol. 2018 Feb 21;9:126. doi: 10.3389/fphys.2018.00126. eCollection 2018.
• [55] Diagnostic potential of sarcoplasmic myxovirus resistance protein A expression in subsets of dermatomyositis.Neuropathol Appl Neurobiol. 2019 Aug;45(5):513-522. doi: 10.1111/nan.12519. Epub 2018 Nov 22.
• [56] Positive association of genetic variations in the phospholipase C-like 1 gene with dermatomyositis in Chinese Han.Immunol Res. 2016 Feb;64(1):204-12. doi: 10.1007/s12026-015-8738-x.
• [57] The major dermatomyositis-specific Mi-2 autoantigen is a presumed helicase involved in transcriptional activation.Arthritis Rheum. 1995 Oct;38(10):1389-99. doi: 10.1002/art.1780381006.
• [58] Facts and controversies in mixed connective tissue disease.Med Clin (Barc). 2018 Jan 12;150(1):26-32. doi: 10.1016/j.medcli.2017.06.066. Epub 2017 Aug 31.
• [59] Splicing factor proline/glutamine-rich is a novel autoantigen of dermatomyositis and associated with anti-melanoma differentiation-associated gene 5 antibody.J Autoimmun. 2017 Feb;77:116-122. doi: 10.1016/j.jaut.2016.11.006. Epub 2016 Dec 3.
• [60] Expression of the intermediate filament protein synemin in myofibrillar myopathies and other muscle diseases.Acta Neuropathol. 2003 Jul;106(1):1-7. doi: 10.1007/s00401-003-0695-0. Epub 2003 Apr 1.
• [61] Cluster Analysis Using Anti-Aminoacyl-tRNA Synthetases and SS-A/Ro52 antibodies in Patients With Polymyositis/Dermatomyositis.J Clin Rheumatol. 2019 Sep;25(6):246-251. doi: 10.1097/RHU.0000000000000836.